- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01222299
Safety, Pharmacokinetics, and Efficacy of Bepotastine Besilate Nasal Product After Ragweed Pollen Exposure in an Environmental Chamber
October 1, 2020 updated by: Bausch & Lomb Incorporated
The purpose of this study is to examine the safety and efficacy of bepotastine besilate nasal product in seasonal allergic rhinitis patients.
Study Overview
Status
Completed
Conditions
Study Type
Interventional
Enrollment (Actual)
89
Phase
- Phase 2
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
Irvine, California, United States, 92618
- ISTA Pharmaceuticals, Inc.
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Subjects 18 to 65 years of age with a positive skin prick test with ragweed allergen
Exclusion Criteria:
- No active respiratory tract infection
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: DOUBLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Arm 1 - Low Dose
bepotastine besilate nasal product - low dose
|
sterile nasal product
|
EXPERIMENTAL: Arm 2 - Medium Dose
bepotastine besilate nasal product - medium dose
|
sterile nasal product
|
EXPERIMENTAL: Arm 3 - High Dose
bepotastine besilate nasal product - high dose
|
sterile nasal product
|
PLACEBO_COMPARATOR: Arm 4 - Placebo
placebo comparator nasal product
|
sterile nasal product
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mean Change From Baseline (Pre-Dose) in Subject-rated Instantaneous TNSS
Time Frame: Baseline, 20 days
|
Total nasal symptom scores (TNSS) was the summed scores for nasal pruritus [itching], rhinorrhea [runny nose], nasal congestion, and sneezing.
Individual nasal symptoms were rated on a 4-point scale from 0-3 (0=Absent, 1=Mild, 2=Moderate, 3=Severe), with no half-unit assessments.
TNSS was the sum score of 4 nasal symptoms with a maximum score for increased allergic response of 12 units.
The minimum possible total score was 0.
|
Baseline, 20 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
May 1, 2010
Primary Completion (ACTUAL)
August 1, 2010
Study Completion (ACTUAL)
August 1, 2010
Study Registration Dates
First Submitted
October 14, 2010
First Submitted That Met QC Criteria
October 15, 2010
First Posted (ESTIMATE)
October 18, 2010
Study Record Updates
Last Update Posted (ACTUAL)
October 5, 2020
Last Update Submitted That Met QC Criteria
October 1, 2020
Last Verified
October 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Infections
- Respiratory Tract Infections
- Respiratory Tract Diseases
- Immune System Diseases
- Hypersensitivity, Immediate
- Otorhinolaryngologic Diseases
- Respiratory Hypersensitivity
- Hypersensitivity
- Nose Diseases
- Rhinitis
- Rhinitis, Allergic
- Rhinitis, Allergic, Seasonal
- Anti-Allergic Agents
- Bepotastine besilate
Other Study ID Numbers
- S00032
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Seasonal Allergic Rhinitis
-
Glenmark Specialty S.A.CompletedSeasonal Allergic Rhinitis (SAR)United States
-
UCB PharmaCompletedRhinitis | Allergic | Seasonal
-
Glenmark Specialty S.A.CompletedSeasonal Allergic Rhinitis (SAR)United States
-
UCB PharmaCompleted
-
SanofiCompleted
-
SanofiCompleted
-
BayerCompletedRhinitis | Seasonal Rhinitis
-
University of East AngliaNorfolk and Norwich University Hospitals NHS Foundation Trust; Quadram Institute... and other collaboratorsCompletedAsthma | Grass Allergy | Seasonal Affective RhinitisUnited Kingdom
-
GlaxoSmithKlineCompletedRhinitis, Allergic, Perennial and SeasonalUnited States
-
Organon and CoCompletedPerennial Allergic Rhinitis | Seasonal Allergic Rhinitis
Clinical Trials on bepotastine besilate nasal product - low dose
-
Bausch & Lomb IncorporatedCompletedSeasonal Allergic RhinitisUnited States
-
Merck Sharp & Dohme LLCCompletedSeasonal Allergic Rhinitis
-
Amway (China) R&D CenterRecruiting
-
Universidad Católica San Antonio de MurciaRecruitingBeta Alanine SupplementationSpain
-
Acerus Pharmaceuticals CorporationCompletedFemale Sexual DysfunctionUnited States
-
Azelon PharmaceuticalsUnknown
-
Michael A. Rogawski, MD, PhDUnited States Department of DefenseCompletedTraumatic Brain Injury | Posttraumatic EpilepsyUnited States
-
Oyster Point Pharma, Inc.CompletedLong Term Follow up Dry Eye DiseaseUnited States